Natural Product (NP) Details
General Information of the NP (ID: NP5888) | |||||
---|---|---|---|---|---|
Name |
Cucurbitacin B
|
||||
Synonyms |
Cucurbitacin B; 6199-67-3; Datisca principle B; Datiscn Principle B; 1,2-Dihydro-alpha-elaterin; UNII-0115W5MABF; 0115W5MABF; CHEBI:3941; CUCURBITACIN R - DATISCA PRINCIPLE B; NSC49451; Cucurbitacin-B; Cucurbitacin B hydrate; [(E,6R)-6-[(2S,8S,9R,10R,13R,14S,16R,17R)-2,16-dihydroxy-4,4,9,13,14-pentamethyl-3,11-dioxo-2,7,8,10,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl] acetate; Cucurbitacine (B); Cucurbitacine B; (R,E)-6-((2S,8S,9R,10R,13R,14S,16R,17R)-2,16-dihydroxy-4,4,9,13,14-pentamethyl-3,11-dioxo-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl acetate; MLS002702988; HSDB 3476; 19-nor-9.beta.,23-diene-3,11,22-trione, 9-methyl-2.beta.,16.alpha.,20,25-tetrahydroxy-, 25-acetate; 19-Norlanosta-5,11,22-trione, 25-(acetyloxy)-2,16,20-trihydroxy-9-methyl-, (2.beta.,9.beta.,10.alpha.,16.alpha.,23E)-; C32H46O8; NSC 49451; NSC 144154; cucurbitacin B derivatives; SCHEMBL231815; CHEMBL508185; HY-N0416; ZINC4097797; LMST01010104; MFCD07778083; NSC-49451; NSC144154; s8165; AKOS015897085; CCG-270043; CS-3816; NSC-144154; 25-(Acetyloxy)-2,16,20-trihydroxy-9-methyl-19-norlanosta-5,23-diene-3,11,22-trione; 19-Nor-9beta,10alpha-lanosta-5,23-diene-3,11,22-trione, 2beta,16alpha,20,25-tetrahydroxy-9-methyl-, 25-acetate; 19-Norlanosta-5,23-diene-3,11,22-trione, 25-(acetyloxy)-2,16,20-trihydroxy-9-methyl-, (2beta,9beta,10alpha,16alpha,23E)-; Cucurbitacin B hydrate, >=97% (HPLC); N2787; X1115; C08794; 199C673; Q-100715; Q27106259; UNII-W3RWP6CB48 component IXQKXEUSCPEQRD-DKRGWESNSA-N; (2S,4R,23E)-2,16beta,20-trihydroxy-9beta,10,14-trimethyl-1,11,22-trioxo-4,9-cyclo-9,10-secocholesta-5,23-dien-25-yl acetate; (3E,6R)-6-[(1R,2R,4S,10S,11S,13R,14R,15R)-4,13-dihydroxy-1,6,6,11,15-pentamethyl-5,17-dioxotetracyclo[8.7.0.0?,?.0??,??]heptadec-7-en-14-yl]-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl acetate; 19-Nor-9-beta,10-alpha-lanosta-5,23-diene-3,11,22-trione, 2-beta,16-alpha,20,25-tetrahydroxy-9-methyl-, 25-acetate; 19-Norlanosta-5,11,22-trione, 25-(acetyloxy)-2,16,20-trihydroxy-9-methyl-, [2.beta.,.gamma.,.beta.,10.alpha.,16.alpha.]-; 19-Norlanosta-5,23-diene-3,11,22-trione, 25-(acetyloxy)-2,16,20-trihydroxy-9-methyl-, (2beta,9beta,10alpha,16alpha,23E)- (9CI); 2beta,16alpha,20,25-tetrahydroxy-9-methyl-19-nor-9beta,10alpha-lanosta-5,23-diene-3,11,22-trione, 25-acetate; 2beta,16alpha,20,25-tetrahydroxy-9-methyl-3,11,22-trioxo-19-nor-9beta,10alpha-lanosta-5,23-dien-25-yl acetate
Click to Show/Hide
|
||||
Species Origin | Cucurbitaceae ... | Click to Show/Hide | |||
Cucurbitaceae | |||||
Disease | Stomach cancer [ICD-11: 2B72] | Investigative | [1] | ||
Structure |
Click to Download Mol2D MOL |
||||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C32H46O8
|
||||
PubChem CID | |||||
Canonical SMILES |
CC(=O)OC(C)(C)C=CC(=O)C(C)(C1C(CC2(C1(CC(=O)C3(C2CC=C4C3CC(C(=O)C4(C)C)O)C)C)C)O)O
|
||||
InChI |
1S/C32H46O8/c1-17(33)40-27(2,3)13-12-23(36)32(9,39)25-21(35)15-29(6)22-11-10-18-19(14-20(34)26(38)28(18,4)5)31(22,8)24(37)16-30(25,29)7/h10,12-13,19-22,25,34-35,39H,11,14-16H2,1-9H3/b13-12+/t19-,20+,21-,22+,25+,29+,30-,31+,32+/m1/s1
|
||||
InChIKey |
IXQKXEUSCPEQRD-DKRGWESNSA-N
|
||||
CAS Number |
CAS 6199-67-3
|
||||
ChEBI ID | |||||
Herb ID | |||||
SymMap ID | |||||
TCMSP ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Doxorubicin | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | 8505C | CVCL_1054 | Thyroid gland anaplastic carcinoma | Homo sapiens | ||
CAL-62 | CVCL_1112 | Thyroid gland anaplastic carcinoma | Homo sapiens | |||
Experimental
Result(s) |
Doxorubicin has a synergistic cytotoxicity with cucurbitacin B in anaplastic thyroid carcinoma cells. | |||||
Cisplatin | Bladder cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | MB49 | CVCL_7076 | Bladder transitional cell carcinoma | Mus musculus | ||
In-vivo Model | To establish a syngeneic mouse bladder tumor model, 1 * 106 MB49 cells in 100 uL cold PBS were injected subcutaneously into the right flank of the each C57BL/6 mouse strain. | |||||
Experimental
Result(s) |
Cucurbitacin B and cisplatin induce the cell death pathways in MB49 mouse bladder cancer model. | |||||
Gamma-ray irradiation | Brain metastases | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [4] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | SK-BR-3 | CVCL_0033 | Breast adenocarcinoma | Homo sapiens | ||
MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | |||
MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | |||
Experimental
Result(s) |
Cucurbitacin B causes increased radiation sensitivity of human breast cancer cells via G2/M cell cycle arrest. | |||||
Gefitinib | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [5] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | ||
HT-29 | CVCL_0320 | Colon adenocarcinoma | Homo sapiens | |||
Experimental
Result(s) |
CuB plus Gef treatment caused a significant growth and cell cycle inhibition and induced apoptosis in both cell lines. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | ATP-citrate synthase (ACLY) | Molecule Info | [6] | |
Extracellular signal-regulated kinase 1 (ERK1) | Molecule Info | [7] | ||
Extracellular signal-regulated kinase 2 (ERK2) | Molecule Info | [7] | ||
Protein kinase B alpha (AKT1) | Molecule Info | [7] | ||
Serine/threonine-protein kinase mTOR (mTOR) | Molecule Info | [7] | ||
Tyrosine kinase receptor Erbb2 (HER2) | Molecule Info | [8] | ||
BioCyc | Acetyl-CoA biosynthesis from citrate | Click to Show/Hide | ||
KEGG Pathway | MAPK signaling pathway | Click to Show/Hide | ||
2 | ErbB signaling pathway | |||
3 | Ras signaling pathway | |||
4 | Rap1 signaling pathway | |||
5 | cGMP-PKG signaling pathway | |||
6 | cAMP signaling pathway | |||
7 | Chemokine signaling pathway | |||
8 | HIF-1 signaling pathway | |||
9 | FoxO signaling pathway | |||
10 | Sphingolipid signaling pathway | |||
11 | Oocyte meiosis | |||
12 | mTOR signaling pathway | |||
13 | PI3K-Akt signaling pathway | |||
14 | Adrenergic signaling in cardiomyocytes | |||
15 | Vascular smooth muscle contraction | |||
16 | Dorso-ventral axis formation | |||
17 | TGF-beta signaling pathway | |||
18 | Axon guidance | |||
19 | VEGF signaling pathway | |||
20 | Osteoclast differentiation | |||
21 | Focal adhesion | |||
22 | Adherens junction | |||
23 | Gap junction | |||
24 | Signaling pathways regulating pluripotency of stem cells | |||
25 | Platelet activation | |||
26 | Toll-like receptor signaling pathway | |||
27 | NOD-like receptor signaling pathway | |||
28 | Natural killer cell mediated cytotoxicity | |||
29 | T cell receptor signaling pathway | |||
30 | B cell receptor signaling pathway | |||
31 | Fc epsilon RI signaling pathway | |||
32 | Fc gamma R-mediated phagocytosis | |||
33 | TNF signaling pathway | |||
34 | Circadian entrainment | |||
35 | Long-term potentiation | |||
36 | Neurotrophin signaling pathway | |||
37 | Retrograde endocannabinoid signaling | |||
38 | Glutamatergic synapse | |||
39 | Cholinergic synapse | |||
40 | Serotonergic synapse | |||
41 | Long-term depression | |||
42 | Regulation of actin cytoskeleton | |||
43 | Insulin signaling pathway | |||
44 | GnRH signaling pathway | |||
45 | Progesterone-mediated oocyte maturation | |||
46 | Estrogen signaling pathway | |||
47 | Melanogenesis | |||
48 | Prolactin signaling pathway | |||
49 | Thyroid hormone signaling pathway | |||
50 | Oxytocin signaling pathway | |||
51 | Type II diabetes mellitus | |||
52 | Aldosterone-regulated sodium reabsorption | |||
53 | Alzheimer's disease | |||
54 | Prion diseases | |||
55 | Alcoholism | |||
56 | Shigellosis | |||
57 | Salmonella infection | |||
58 | Pertussis | |||
59 | Leishmaniasis | |||
60 | Chagas disease (American trypanosomiasis) | |||
61 | Toxoplasmosis | |||
62 | Tuberculosis | |||
63 | Hepatitis C | |||
64 | Hepatitis B | |||
65 | Influenza A | |||
66 | Pathways in cancer | |||
67 | Viral carcinogenesis | |||
68 | Proteoglycans in cancer | |||
69 | Colorectal cancer | |||
70 | Renal cell carcinoma | |||
71 | Pancreatic cancer | |||
72 | Endometrial cancer | |||
73 | Glioma | |||
74 | Prostate cancer | |||
75 | Thyroid cancer | |||
76 | Melanoma | |||
77 | Bladder cancer | |||
78 | Chronic myeloid leukemia | |||
79 | Acute myeloid leukemia | |||
80 | Non-small cell lung cancer | |||
81 | Central carbon metabolism in cancer | |||
82 | Choline metabolism in cancer | |||
83 | Calcium signaling pathway | |||
84 | MicroRNAs in cancer | |||
85 | AMPK signaling pathway | |||
86 | Apoptosis | |||
87 | Tight junction | |||
88 | Jak-STAT signaling pathway | |||
89 | Dopaminergic synapse | |||
90 | Adipocytokine signaling pathway | |||
91 | Glucagon signaling pathway | |||
92 | Regulation of lipolysis in adipocytes | |||
93 | Non-alcoholic fatty liver disease (NAFLD) | |||
94 | Carbohydrate digestion and absorption | |||
95 | Measles | |||
96 | HTLV-I infection | |||
97 | Epstein-Barr virus infection | |||
98 | Small cell lung cancer | |||
99 | Citrate cycle (TCA cycle) | |||
100 | Metabolic pathways | |||
101 | Biosynthesis of antibiotics | |||
NetPath Pathway | IL5 Signaling Pathway | Click to Show/Hide | ||
2 | TCR Signaling Pathway | |||
3 | TSH Signaling Pathway | |||
4 | TGF_beta_Receptor Signaling Pathway | |||
5 | IL2 Signaling Pathway | |||
Panther Pathway | Alzheimer disease-amyloid secretase pathway | Click to Show/Hide | ||
2 | Angiogenesis | |||
3 | Apoptosis signaling pathway | |||
4 | B cell activation | |||
5 | EGF receptor signaling pathway | |||
6 | Endothelin signaling pathway | |||
7 | FGF signaling pathway | |||
8 | Inflammation mediated by chemokine and cytokine signaling pathway | |||
9 | Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade | |||
10 | Integrin signalling pathway | |||
11 | Interferon-gamma signaling pathway | |||
12 | Interleukin signaling pathway | |||
13 | PDGF signaling pathway | |||
14 | Parkinson disease | |||
15 | TGF-beta signaling pathway | |||
16 | T cell activation | |||
17 | Toll receptor signaling pathway | |||
18 | VEGF signaling pathway | |||
19 | Ras Pathway | |||
20 | Angiotensin II-stimulated signaling through G proteins and beta-arrestin | |||
21 | CCKR signaling map ST | |||
22 | Cadherin signaling pathway | |||
23 | Huntington disease | |||
24 | Hypoxia response via HIF activation | |||
25 | Insulin/IGF pathway-protein kinase B signaling cascade | |||
26 | PI3 kinase pathway | |||
27 | p53 pathway | |||
28 | p53 pathway by glucose deprivation | |||
29 | p53 pathway feedback loops 2 | |||
Pathwhiz Pathway | Phosphatidylinositol Phosphate Metabolism | Click to Show/Hide | ||
2 | Intracellular Signalling Through Adenosine Receptor A2a and Adenosine | |||
3 | Intracellular Signalling Through Adenosine Receptor A2b and Adenosine | |||
4 | Fc Epsilon Receptor I Signaling in Mast Cells | |||
5 | Insulin Signalling | |||
6 | Leucine Stimulation on Insulin Signaling | |||
7 | Transfer of Acetyl Groups into Mitochondria | |||
Pathway Interaction Database | Fc-epsilon receptor I signaling in mast cells | Click to Show/Hide | ||
2 | Endothelins | |||
3 | BCR signaling pathway | |||
4 | Signaling events mediated by PRL | |||
5 | ErbB4 signaling events | |||
6 | GMCSF-mediated signaling events | |||
7 | Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) | |||
8 | S1P3 pathway | |||
9 | EPHB forward signaling | |||
10 | Osteopontin-mediated events | |||
11 | S1P4 pathway | |||
12 | Presenilin action in Notch and Wnt signaling | |||
13 | TRAIL signaling pathway | |||
14 | CDC42 signaling events | |||
15 | Signaling events regulated by Ret tyrosine kinase | |||
16 | Angiopoietin receptor Tie2-mediated signaling | |||
17 | S1P1 pathway | |||
18 | Regulation of Telomerase | |||
19 | Netrin-mediated signaling events | |||
20 | Role of Calcineurin-dependent NFAT signaling in lymphocytes | |||
21 | Glucocorticoid receptor regulatory network | |||
22 | Arf6 downstream pathway | |||
23 | mTOR signaling pathway | |||
24 | IL2-mediated signaling events | |||
25 | EGF receptor (ErbB1) signaling pathway | |||
26 | Ras signaling in the CD4+ TCR pathway | |||
27 | Ceramide signaling pathway | |||
28 | Integrins in angiogenesis | |||
29 | IFN-gamma pathway | |||
30 | ErbB1 downstream signaling | |||
31 | ATF-2 transcription factor network | |||
32 | ErbB2/ErbB3 signaling events | |||
33 | ALK1 signaling events | |||
34 | PDGFR-beta signaling pathway | |||
35 | Neurotrophic factor-mediated Trk receptor signaling | |||
36 | Syndecan-1-mediated signaling events | |||
37 | Retinoic acid receptors-mediated signaling | |||
38 | Nongenotropic Androgen signaling | |||
39 | CXCR3-mediated signaling events | |||
40 | VEGFR1 specific signals | |||
41 | Regulation of cytoplasmic and nuclear SMAD2/3 signaling | |||
42 | Signaling events mediated by Stem cell factor receptor (c-Kit) | |||
43 | Signaling events mediated by VEGFR1 and VEGFR2 | |||
44 | Syndecan-2-mediated signaling events | |||
45 | Cellular roles of Anthrax toxin | |||
46 | S1P2 pathway | |||
47 | Trk receptor signaling mediated by the MAPK pathway | |||
48 | Downstream signaling in naï | |||
49 | ||||
50 | VEGFR3 signaling in lymphatic endothelium | |||
51 | Alpha-synuclein signaling | |||
52 | FGF signaling pathway | |||
53 | ErbB receptor signaling network | |||
54 | a6b1 and a6b4 Integrin signaling | |||
55 | Validated targets of C-MYC transcriptional repression | |||
56 | Regulation of nuclear SMAD2/3 signaling | |||
57 | LPA receptor mediated events | |||
58 | Insulin Pathway | |||
59 | IL4-mediated signaling events | |||
60 | TCR signaling in naï | |||
61 | ||||
62 | Plasma membrane estrogen receptor signaling | |||
63 | CD40/CD40L signaling | |||
64 | Signaling events mediated by PTP1B | |||
65 | Coregulation of Androgen receptor activity | |||
66 | Reelin signaling pathway | |||
67 | Integrin-linked kinase signaling | |||
68 | TCR signaling in naï | |||
69 | FAS (CD95) signaling pathway | |||
70 | Thromboxane A2 receptor signaling | |||
71 | FOXA2 and FOXA3 transcription factor networks | |||
72 | CXCR4-mediated signaling events | |||
73 | IGF1 pathway | |||
74 | FoxO family signaling | |||
75 | IL2 signaling events mediated by PI3K | |||
76 | p75(NTR)-mediated signaling | |||
77 | E-cadherin signaling in the nascent adherens junction | |||
78 | amb2 Integrin signaling | |||
79 | IL6-mediated signaling events | |||
80 | E-cadherin signaling in keratinocytes | |||
81 | Nephrin/Neph1 signaling in the kidney podocyte | |||
82 | IL8- and CXCR2-mediated signaling events | |||
83 | Signaling events mediated by the Hedgehog family | |||
84 | Hedgehog signaling events mediated by Gli proteins | |||
85 | Caspase Cascade in Apoptosis | |||
86 | Aurora A signaling | |||
87 | Insulin-mediated glucose transport | |||
88 | Class I PI3K signaling events mediated by Akt | |||
89 | IL8- and CXCR1-mediated signaling events | |||
90 | HIF-1-alpha transcription factor network | |||
91 | p53 pathway | |||
92 | Trk receptor signaling mediated by PI3K and PLC-gamma | |||
93 | Class IB PI3K non-lipid kinase events | |||
94 | BMP receptor signaling | |||
95 | Signaling events mediated by focal adhesion kinase | |||
96 | IL12-mediated signaling events | |||
97 | LKB1 signaling events | |||
98 | EGFR-dependent Endothelin signaling events | |||
Reactome | MAPK3 (ERK1) activation | Click to Show/Hide | ||
2 | RAF-independent MAPK1/3 activation | |||
3 | ISG15 antiviral mechanism | |||
4 | ERK/MAPK targets | |||
5 | Regulation of actin dynamics for phagocytic cup formation | |||
6 | Oxidative Stress Induced Senescence | |||
7 | Senescence-Associated Secretory Phenotype (SASP) | |||
8 | Oncogene Induced Senescence | |||
9 | FCERI mediated MAPK activation | |||
10 | Regulation of HSF1-mediated heat shock response | |||
11 | NCAM signaling for neurite out-growth | |||
12 | Activation of the AP-1 family of transcription factors | |||
13 | Thrombin signalling through proteinase activated receptors (PARs) | |||
14 | Negative regulation of FGFR1 signaling | |||
15 | Negative regulation of FGFR2 signaling | |||
16 | Negative regulation of FGFR3 signaling | |||
17 | Negative regulation of FGFR4 signaling | |||
18 | RHO GTPases Activate WASPs and WAVEs | |||
19 | RAF/MAP kinase cascade | |||
20 | MAP2K and MAPK activation | |||
21 | Negative feedback regulation of MAPK pathway | |||
22 | Negative regulation of MAPK pathway | |||
23 | Signal attenuation | |||
24 | Advanced glycosylation endproduct receptor signaling | |||
25 | Gastrin-CREB signalling pathway via PKC and MAPK | |||
26 | Growth hormone receptor signaling | |||
27 | SHC1 events in ERBB2 signaling | |||
28 | PLCG1 events in ERBB2 signaling | |||
29 | PIP3 activates AKT signaling | |||
30 | GRB2 events in ERBB2 signaling | |||
31 | PI3K events in ERBB2 signaling | |||
32 | Constitutive Signaling by Aberrant PI3K in Cancer | |||
33 | Sema4D induced cell migration and growth-cone collapse | |||
34 | Activation of BAD and translocation to mitochondria | |||
35 | GPVI-mediated activation cascade | |||
36 | Translocation of GLUT4 to the plasma membrane | |||
37 | Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | |||
38 | AKT phosphorylates targets in the cytosol | |||
39 | AKT phosphorylates targets in the nucleus | |||
40 | Negative regulation of the PI3K/AKT network | |||
41 | eNOS activation | |||
42 | AKT-mediated inactivation of FOXO1A | |||
43 | Integrin alphaIIb beta3 signaling | |||
44 | Deactivation of the beta-catenin transactivating complex | |||
45 | CD28 dependent PI3K/Akt signaling | |||
46 | CTLA4 inhibitory signaling | |||
47 | G beta:gamma signalling through PI3Kgamma | |||
48 | KSRP (KHSRP) binds and destabilizes mRNA | |||
49 | VEGFR2 mediated vascular permeability | |||
50 | TP53 Regulates Metabolic Genes | |||
51 | Constitutive Signaling by AKT1 E17K in Cancer | |||
52 | ChREBP activates metabolic gene expression | |||
53 | Fatty Acyl-CoA Biosynthesis | |||
54 | MAPK1 (ERK2) activation | |||
55 | Golgi Cisternae Pericentriolar Stack Reorganization | |||
56 | Recycling pathway of L1 | |||
57 | CREB phosphorylation through the activation of Ras | |||
58 | Macroautophagy | |||
59 | mTORC1-mediated signalling | |||
60 | HSF1-dependent transactivation | |||
WikiPathways | Toll-like receptor signaling pathway | Click to Show/Hide | ||
2 | Serotonin Receptor 4/6/7 and NR3C Signaling | |||
3 | Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||
4 | Serotonin HTR1 Group and FOS Pathway | |||
5 | TCR Signaling Pathway | |||
6 | Hypothetical Network for Drug Addiction | |||
7 | EPO Receptor Signaling | |||
8 | TGF Beta Signaling Pathway | |||
9 | Regulation of Actin Cytoskeleton | |||
10 | IL-2 Signaling Pathway | |||
11 | Insulin Signaling | |||
12 | MAPK Cascade | |||
13 | IL-4 Signaling Pathway | |||
14 | MAPK Signaling Pathway | |||
15 | IL-6 signaling pathway | |||
16 | Signaling of Hepatocyte Growth Factor Receptor | |||
17 | Kit receptor signaling pathway | |||
18 | TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer | |||
19 | IL-3 Signaling Pathway | |||
20 | Cardiac Hypertrophic Response | |||
21 | MAP kinase activation in TLR cascade | |||
22 | Fc epsilon receptor (FCERI) signaling | |||
23 | RAF/MAP kinase cascade | |||
24 | Structural Pathway of Interleukin 1 (IL-1) | |||
25 | Genes and (Common) Pathways Underlying Drug Addiction | |||
26 | Signal Transduction of S1P Receptor | |||
27 | PDGF Pathway | |||
28 | Alpha 6 Beta 4 signaling pathway | |||
29 | Spinal Cord Injury | |||
30 | BDNF signaling pathway | |||
31 | Integrated Pancreatic Cancer Pathway | |||
32 | Oncostatin M Signaling Pathway | |||
33 | Corticotropin-releasing hormone | |||
34 | Interleukin-11 Signaling Pathway | |||
35 | AGE/RAGE pathway | |||
36 | TNF alpha Signaling Pathway | |||
37 | Prostate Cancer | |||
38 | Signaling Pathways in Glioblastoma | |||
39 | TSLP Signaling Pathway | |||
40 | IL-9 Signaling Pathway | |||
41 | IL17 signaling pathway | |||
42 | Alzheimers Disease | |||
43 | IL-7 Signaling Pathway | |||
44 | TWEAK Signaling Pathway | |||
45 | FSH signaling pathway | |||
46 | Leptin signaling pathway | |||
47 | RANKL/RANK Signaling Pathway | |||
48 | IL-1 signaling pathway | |||
49 | Thrombin signalling through proteinase activated receptors (PARs) | |||
50 | Signaling by Insulin receptor | |||
51 | Signaling by FGFR | |||
52 | RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription | |||
53 | L1CAM interactions | |||
54 | Advanced glycosylation endproduct receptor signaling | |||
55 | Apoptosis Modulation and Signaling | |||
56 | MicroRNAs in cardiomyocyte hypertrophy | |||
57 | Regulation of toll-like receptor signaling pathway | |||
58 | Osteopontin Signaling | |||
59 | IL-5 Signaling Pathway | |||
60 | DNA Damage Response (only ATM dependent) | |||
61 | ErbB Signaling Pathway | |||
62 | EGF/EGFR Signaling Pathway | |||
63 | Focal Adhesion | |||
64 | Extracellular vesicle-mediated signaling in recipient cells | |||
65 | Bladder Cancer | |||
66 | Signaling by ERBB2 | |||
67 | miR-targeted genes in muscle cell - TarBase | |||
68 | Semaphorin interactions | |||
69 | Notch Signaling Pathway | |||
70 | Endochondral Ossification | |||
71 | TGF beta Signaling Pathway | |||
72 | Wnt Signaling Pathway Netpath | |||
73 | Copper homeostasis | |||
74 | Apoptosis-related network due to altered Notch3 in ovarian cancer | |||
75 | Translocation of GLUT4 to the Plasma Membrane | |||
76 | Regulation of mRNA Stability by Proteins that Bind AU-rich Elements | |||
77 | PIP3 activates AKT signaling | |||
78 | T-Cell Receptor and Co-stimulatory Signaling | |||
79 | Primary Focal Segmental Glomerulosclerosis FSGS | |||
80 | Apoptosis | |||
81 | B Cell Receptor Signaling Pathway | |||
82 | Regulation of Microtubule Cytoskeleton | |||
83 | TSH signaling pathway | |||
84 | Integrated Breast Cancer Pathway | |||
85 | SREBP signalling | |||
86 | Integrated Cancer pathway | |||
87 | Metabolism of nitric oxide | |||
88 | Integrin-mediated Cell Adhesion | |||
89 | TFs Regulate miRNAs related to cardiac hypertrophy | |||
90 | Angiogenesis | |||
91 | TOR Signaling | |||
92 | AMPK Signaling | |||
93 | Androgen receptor signaling pathway | |||
94 | Fatty Acid Biosynthesis | |||
95 | TCA Cycle and PDHc | |||
96 | Butyrate-induced histone acetylation | |||
97 | Integration of energy metabolism | |||
98 | Fatty acid, triacylglycerol, and ketone body metabolism | |||
99 | Vitamin A and Carotenoid Metabolism | |||
100 | Senescence and Autophagy in Cancer | |||
101 | Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||
102 | Nanoparticle-mediated activation of receptor signaling | |||
103 | EBV LMP1 signaling | |||
104 | Nifedipine Activity | |||
105 | Aryl Hydrocarbon Receptor | |||
106 | Endothelin Pathways | |||
107 | Opioid Signalling | |||
108 | Heart Development | |||
109 | Type II diabetes mellitus | |||
110 | Physiological and Pathological Hypertrophy of the Heart | |||
111 | Interferon type I signaling pathways | |||
112 | Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | |||
113 | Polycystic Kidney Disease Pathway | |||
114 | SREBF and miR33 in cholesterol and lipid homeostasis | |||
115 | Costimulation by the CD28 family |